Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

IN VITRO 3D PHENOTYPIC DRUG SCREEN IDENTIFIES CELASTROL AS AN EFFECTIVE IN VIVO INHIBITOR OF POLYCYSTIC KIDNEY DISEASE.

Booij TH, Leonhard WN, Bange H, Yan K, Fokkelman M, Plugge AJ, Veraar KAM, Dauwerse JG, van Westen GJP, van de Water B, Price LS, Peters DJM.

J Mol Cell Biol. 2019 May 8. pii: mjz029. doi: 10.1093/jmcb/mjz029. [Epub ahead of print]

PMID:
31065693
2.

Folate-dactolisib conjugates for targeting tubular cells in polycystic kidneys.

Shi H, Leonhard WN, Sijbrandi NJ, van Steenbergen MJ, Fens MHAM, van de Dikkenberg JB, Toraño JS, Peters DJM, Hennink WE, Kok RJ.

J Control Release. 2019 Jan 10;293:113-125. doi: 10.1016/j.jconrel.2018.11.019. Epub 2018 Nov 23.

3.

Comparative transcriptomics of shear stress treated Pkd1-/- cells and pre-cystic kidneys reveals pathways involved in early polycystic kidney disease.

Kunnen SJ, Malas TB, Formica C, Leonhard WN, 't Hoen PAC, Peters DJM.

Biomed Pharmacother. 2018 Dec;108:1123-1134. doi: 10.1016/j.biopha.2018.07.178. Epub 2018 Oct 1.

4.

Polycystin-1 dysfunction impairs electrolyte and water handling in a renal precystic mouse model for ADPKD.

Verschuren EHJ, Mohammed SG, Leonhard WN, Overmars-Bos C, Veraar K, Hoenderop JGJ, Bindels RJM, Peters DJM, Arjona FJ.

Am J Physiol Renal Physiol. 2018 Sep 1;315(3):F537-F546. doi: 10.1152/ajprenal.00622.2017. Epub 2018 May 16.

PMID:
29767557
5.

High-Throughput Phenotypic Screening of Kinase Inhibitors to Identify Drug Targets for Polycystic Kidney Disease.

Booij TH, Bange H, Leonhard WN, Yan K, Fokkelman M, Kunnen SJ, Dauwerse JG, Qin Y, van de Water B, van Westen GJP, Peters DJM, Price LS.

SLAS Discov. 2017 Sep;22(8):974-984. doi: 10.1177/2472555217716056. Epub 2017 Jun 23.

6.

Fluid shear stress-induced TGF-β/ALK5 signaling in renal epithelial cells is modulated by MEK1/2.

Kunnen SJ, Leonhard WN, Semeins C, Hawinkels LJAC, Poelma C, Ten Dijke P, Bakker A, Hierck BP, Peters DJM.

Cell Mol Life Sci. 2017 Jun;74(12):2283-2298. doi: 10.1007/s00018-017-2460-x. Epub 2017 Feb 6.

7.

Meta-analysis of polycystic kidney disease expression profiles defines strong involvement of injury repair processes.

Malas TB, Formica C, Leonhard WN, Rao P, Granchi Z, Roos M, Peters DJ, 't Hoen PA.

Am J Physiol Renal Physiol. 2017 Apr 1;312(4):F806-F817. doi: 10.1152/ajprenal.00653.2016. Epub 2017 Feb 1. Erratum in: Am J Physiol Renal Physiol. 2018 Jan 1;314(1):F140.

8.

STAT5 drives abnormal proliferation in autosomal dominant polycystic kidney disease.

Fragiadaki M, Lannoy M, Themanns M, Maurer B, Leonhard WN, Peters DJ, Moriggl R, Ong AC.

Kidney Int. 2017 Mar;91(3):575-586. doi: 10.1016/j.kint.2016.10.039. Epub 2017 Jan 16.

9.

Variable Cyst Development in Autosomal Dominant Polycystic Kidney Disease: The Biologic Context.

Leonhard WN, Happe H, Peters DJ.

J Am Soc Nephrol. 2016 Dec;27(12):3530-3538. Epub 2016 Aug 4. Review.

10.

Inhibition of Activin Signaling Slows Progression of Polycystic Kidney Disease.

Leonhard WN, Kunnen SJ, Plugge AJ, Pasternack A, Jianu SB, Veraar K, El Bouazzaoui F, Hoogaars WM, Ten Dijke P, Breuning MH, De Heer E, Ritvos O, Peters DJ.

J Am Soc Nephrol. 2016 Dec;27(12):3589-3599. Epub 2016 Mar 28.

11.

Proteomics of Urinary Vesicles Links Plakins and Complement to Polycystic Kidney Disease.

Salih M, Demmers JA, Bezstarosti K, Leonhard WN, Losekoot M, van Kooten C, Gansevoort RT, Peters DJ, Zietse R, Hoorn EJ; DIPAK Consortium.

J Am Soc Nephrol. 2016 Oct;27(10):3079-3092. Epub 2016 Mar 3.

12.

Urine Fetuin-A is a biomarker of autosomal dominant polycystic kidney disease progression.

Piazzon N, Bernet F, Guihard L, Leonhard WN, Urfer S, Firsov D, Chehade H, Vogt B, Piergiovanni S, Peters DJ, Bonny O, Constam DB.

J Transl Med. 2015 Mar 30;13:103. doi: 10.1186/s12967-015-0463-7.

13.

Scattered Deletion of PKD1 in Kidneys Causes a Cystic Snowball Effect and Recapitulates Polycystic Kidney Disease.

Leonhard WN, Zandbergen M, Veraar K, van den Berg S, van der Weerd L, Breuning M, de Heer E, Peters DJ.

J Am Soc Nephrol. 2015 Jun;26(6):1322-33. doi: 10.1681/ASN.2013080864. Epub 2014 Oct 31.

14.

Cyst expansion and regression in a mouse model of polycystic kidney disease.

Happé H, van der Wal AM, Salvatori DC, Leonhard WN, Breuning MH, de Heer E, Peters DJ.

Kidney Int. 2013 Jun;83(6):1099-108. doi: 10.1038/ki.2013.13. Epub 2013 Mar 6.

15.

Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease.

Novalic Z, van der Wal AM, Leonhard WN, Koehl G, Breuning MH, Geissler EK, de Heer E, Peters DJ.

J Am Soc Nephrol. 2012 May;23(5):842-53. doi: 10.1681/ASN.2011040340. Epub 2012 Feb 16.

16.

Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: optimal timing and dosing of the drug.

Meijer E, Gansevoort RT, de Jong PE, van der Wal AM, Leonhard WN, de Krey SR, van den Born J, Mulder GM, van Goor H, Struck J, de Heer E, Peters DJ.

Nephrol Dial Transplant. 2011 Aug;26(8):2445-53. doi: 10.1093/ndt/gfr069. Epub 2011 Mar 10.

PMID:
21393612
17.

Altered Hippo signalling in polycystic kidney disease.

Happé H, van der Wal AM, Leonhard WN, Kunnen SJ, Breuning MH, de Heer E, Peters DJ.

J Pathol. 2011 May;224(1):133-42. doi: 10.1002/path.2856. Epub 2011 Mar 7.

PMID:
21381034
18.

Curcumin inhibits cystogenesis by simultaneous interference of multiple signaling pathways: in vivo evidence from a Pkd1-deletion model.

Leonhard WN, van der Wal A, Novalic Z, Kunnen SJ, Gansevoort RT, Breuning MH, de Heer E, Peters DJ.

Am J Physiol Renal Physiol. 2011 May;300(5):F1193-202. doi: 10.1152/ajprenal.00419.2010. Epub 2011 Feb 23.

19.

Elevated TGFbeta-Smad signalling in experimental Pkd1 models and human patients with polycystic kidney disease.

Hassane S, Leonhard WN, van der Wal A, Hawinkels LJ, Lantinga-van Leeuwen IS, ten Dijke P, Breuning MH, de Heer E, Peters DJ.

J Pathol. 2010 Sep;222(1):21-31. doi: 10.1002/path.2734.

PMID:
20549648
20.

Rapid high-throughput analysis of DNaseI hypersensitive sites using a modified Multiplex Ligation-dependent Probe Amplification approach.

Ohnesorg T, Eggers S, Leonhard WN, Sinclair AH, White SJ.

BMC Genomics. 2009 Sep 4;10:412. doi: 10.1186/1471-2164-10-412.

21.

Toxic tubular injury in kidneys from Pkd1-deletion mice accelerates cystogenesis accompanied by dysregulated planar cell polarity and canonical Wnt signaling pathways.

Happé H, Leonhard WN, van der Wal A, van de Water B, Lantinga-van Leeuwen IS, Breuning MH, de Heer E, Peters DJ.

Hum Mol Genet. 2009 Jul 15;18(14):2532-42. doi: 10.1093/hmg/ddp190. Epub 2009 Apr 28.

PMID:
19401297
22.

Quantification of Cre-mediated recombination by a novel strategy reveals a stable extra-chromosomal deletion-circle in mice.

Leonhard WN, Roelfsema JH, Lantinga-van Leeuwen IS, Breuning MH, Peters DJ.

BMC Biotechnol. 2008 Feb 25;8:18. doi: 10.1186/1472-6750-8-18.

23.

Kidney-specific inactivation of the Pkd1 gene induces rapid cyst formation in developing kidneys and a slow onset of disease in adult mice.

Lantinga-van Leeuwen IS, Leonhard WN, van der Wal A, Breuning MH, de Heer E, Peters DJ.

Hum Mol Genet. 2007 Dec 15;16(24):3188-96. Epub 2007 Oct 11.

PMID:
17932118
24.

Transgenic mice expressing tamoxifen-inducible Cre for somatic gene modification in renal epithelial cells.

Lantinga-van Leeuwen IS, Leonhard WN, van de Wal A, Breuning MH, Verbeek S, de Heer E, Peters DJ.

Genesis. 2006 May;44(5):225-32.

PMID:
16652363
25.

Common regulatory elements in the polycystic kidney disease 1 and 2 promoter regions.

Lantinga-van Leeuwen IS, Leonhard WN, Dauwerse H, Baelde HJ, van Oost BA, Breuning MH, Peters DJ.

Eur J Hum Genet. 2005 May;13(5):649-59.

26.

Lowering of Pkd1 expression is sufficient to cause polycystic kidney disease.

Lantinga-van Leeuwen IS, Dauwerse JG, Baelde HJ, Leonhard WN, van de Wal A, Ward CJ, Verbeek S, Deruiter MC, Breuning MH, de Heer E, Peters DJ.

Hum Mol Genet. 2004 Dec 15;13(24):3069-77. Epub 2004 Oct 20.

PMID:
15496422

Supplemental Content

Loading ...
Support Center